Manufacturing stresses do not differentially impact red blood cells from donors with diabetes.

IF 1.6 4区医学 Q3 HEMATOLOGY

Vox Sanguinis Pub Date : 2025-08-06 DOI:10.1111/vox.70084

Celina Phan, Elyn M Rowe, Mahsa Yazdanbakhsh, Jayme Kurach, Mackenzie Brandon-Coatham, Dana V Devine, James D Johnson, Jason P Acker

{"title":"Manufacturing stresses do not differentially impact red blood cells from donors with diabetes.","authors":"Celina Phan, Elyn M Rowe, Mahsa Yazdanbakhsh, Jayme Kurach, Mackenzie Brandon-Coatham, Dana V Devine, James D Johnson, Jason P Acker","doi":"10.1111/vox.70084","DOIUrl":null,"url":null,"abstract":"Background and objectives: With the rising prevalence of diabetes and expanded blood donor criteria in Canada, individuals with diabetes are increasingly contributing to the blood supply. However, little is known about how routine manufacturing affects red blood cells (RBCs) from this group. This study examined RBC differences in donors with type 1 (T1D) or type 2 diabetes (T2D) following processing to generate red cell concentrates (RCCs).Materials and methods: Whole blood (WB) donations were collected from voluntary T1D (n = 12), T2D (n = 11) and non-diabetic age/sex-matched (n = 23) donors. Donations were processed via red cell filtration to generate RCCs. At donation, 2.7-mL of WB was collected into EDTA tubes, and 70 mL of processed RCCs was aliquoted into satellite bags. WB-EDTA tubes and RCC satellite bags were characterized on Day 2 post collection.Results: Donors with T1D and T2D had similar, but higher glycated haemoglobin (HbA1c) levels than matched controls (p < 0.001). Processing increased RBC count, haemoglobin and haematocrit in all groups (p < 0.0001). Donors with T2D had decreased mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC) compared to controls, both pre and post processing (p < 0.05), with a similar trend in p50 (pre: p < 0.01; post: p < 0.05).Conclusion: Blood component manufacturing did not exacerbate stress on RBCs from donors with diabetes. Donors with T2D had altered MCH, MCHC and p50 compared to matched controls, which persisted after processing. These findings emphasize the importance of donor health on blood product quality.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70084","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: With the rising prevalence of diabetes and expanded blood donor criteria in Canada, individuals with diabetes are increasingly contributing to the blood supply. However, little is known about how routine manufacturing affects red blood cells (RBCs) from this group. This study examined RBC differences in donors with type 1 (T1D) or type 2 diabetes (T2D) following processing to generate red cell concentrates (RCCs).

Materials and methods: Whole blood (WB) donations were collected from voluntary T1D (n = 12), T2D (n = 11) and non-diabetic age/sex-matched (n = 23) donors. Donations were processed via red cell filtration to generate RCCs. At donation, 2.7-mL of WB was collected into EDTA tubes, and 70 mL of processed RCCs was aliquoted into satellite bags. WB-EDTA tubes and RCC satellite bags were characterized on Day 2 post collection.

Results: Donors with T1D and T2D had similar, but higher glycated haemoglobin (HbA1c) levels than matched controls (p < 0.001). Processing increased RBC count, haemoglobin and haematocrit in all groups (p < 0.0001). Donors with T2D had decreased mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC) compared to controls, both pre and post processing (p < 0.05), with a similar trend in p50 (pre: p < 0.01; post: p < 0.05).

Conclusion: Blood component manufacturing did not exacerbate stress on RBCs from donors with diabetes. Donors with T2D had altered MCH, MCHC and p50 compared to matched controls, which persisted after processing. These findings emphasize the importance of donor health on blood product quality.

查看原文本刊更多论文

制造压力对糖尿病献血者红细胞的影响没有差异。

背景和目的：随着加拿大糖尿病患病率的上升和献血者标准的扩大，糖尿病患者对血液供应的贡献越来越大。然而，对于常规制造如何影响这一群体的红细胞（rbc），我们知之甚少。本研究检测了1型（T1D）或2型糖尿病（T2D）供体在生成红细胞浓缩物（RCCs）后的红细胞差异。材料和方法：收集自愿T1D （n = 12）、T2D （n = 11）和非糖尿病年龄/性别匹配（n = 23）献血者的全血（WB）。捐献通过红细胞过滤生成红细胞。捐赠时，将2.7 mL WB收集到EDTA管中，将70 mL处理后的rcc放入卫星袋中。WB-EDTA管和RCC卫星袋在收集后第2天被表征。结果：与匹配的对照组相比，T1D和T2D供者的糖化血红蛋白（HbA1c）水平相似，但更高(p)。结论：血液成分制造不会加剧糖尿病供者红细胞的应激。与匹配的对照组相比，患有T2D的供者改变了MCH、MCHC和p50，这种改变在处理后仍然存在。这些发现强调了献血者健康对血液制品质量的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vox Sanguinis 医学-血液学

CiteScore

4.40

自引率

11.10%

发文量

156

审稿时长

6-12 weeks

期刊介绍： Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections: 1) Transfusion - Transmitted Disease and its Prevention: Identification and epidemiology of infectious agents transmissible by blood; Bacterial contamination of blood components; Donor recruitment and selection methods; Pathogen inactivation. 2) Blood Component Collection and Production: Blood collection methods and devices (including apheresis); Plasma fractionation techniques and plasma derivatives; Preparation of labile blood components; Inventory management; Hematopoietic progenitor cell collection and storage; Collection and storage of tissues; Quality management and good manufacturing practice; Automation and information technology. 3) Transfusion Medicine and New Therapies: Transfusion thresholds and audits; Haemovigilance; Clinical trials regarding appropriate haemotherapy; Non-infectious adverse affects of transfusion; Therapeutic apheresis; Support of transplant patients; Gene therapy and immunotherapy. 4) Immunohaematology and Immunogenetics: Autoimmunity in haematology; Alloimmunity of blood; Pre-transfusion testing; Immunodiagnostics; Immunobiology; Complement in immunohaematology; Blood typing reagents; Genetic markers of blood cells and serum proteins: polymorphisms and function; Genetic markers and disease; Parentage testing and forensic immunohaematology. 5) Cellular Therapy: Cell-based therapies; Stem cell sources; Stem cell processing and storage; Stem cell products; Stem cell plasticity; Regenerative medicine with cells; Cellular immunotherapy; Molecular therapy; Gene therapy.